Illumina becomes primary vendor of tumor variant interpretation and
reporting software for pioneering population sequencing project
SAN DIEGO--(BUSINESS WIRE)--Jun. 26, 2017--
Inc. (NASDAQ:ILMN) and Genomics
England announced today that Illumina is the primary variant
interpretation and reporting software vendor for tumor and matched
normal samples characterized as part of the 100,000 Genomes Project.
In a little over a year since Illumina announced the Bioinformatics and
Clinical Interpretation Partnership with Genomics England, the
partnership has now set unified standards for data and
analysis practices using BaseSpace Variant Interpreter software for
tumor variant review.
In the coming months, Genomics England will be expanding the use of
BaseSpace Variant Interpreter for cancer to all NHS Genomic Medicine
Centers, and Illumina will be removing the ‘Beta’ status from its
software offering, and formally launching it for public release later
"We are very pleased to be enabling cutting-edge variant interpretation
and precision genomics for the NHS in cancer,” said Garret Hampton, EVP
Clinical Genomics Group at Illumina. “This is a major milestone for our
population sequencing efforts, and demonstrates Illumina's commitment to
developing software that delivers on the promise of transformative
healthcare through sequencing."
Sir John Chisholm, Executive Chair at Genomics England said: “We believe
that whole genome sequencing will underpin the future of cancer care –
providing greater understanding of the disease and a fuller prognostic
picture for patients. Illumina’s variant interpretation and reporting
software will enable us to deliver better insights from the 100,000
Genomes Project. We are delighted to be working with Illumina alongside
our other delivery partners to drive forward genomic research and
support our ambitions of transforming NHS patient care.”
BaseSpace Variant Interpreter (Beta) enables researchers to perform
rapid annotation, filtering, and interpretation of genomic data. Its
user-friendly, efficient variant-to-report workflow helps summarize
findings into structured reports within a software framework focused on
data security, compliance, and operational efficiency.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical, and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture, and other emerging segments. To learn more, visit www.illumina.com and
This release contains forward-looking statements that involve risks and
uncertainties. Examples of forward-looking statements include, but are
not limited to, statements we make regarding the expected availability
dates for new products and services and FDA submission dates and
intentions for certain products and services. Important factors that
could cause actual results to differ materially from those in any
forward-looking statements include challenges inherent in developing,
manufacturing, and launching new products and services, and the other
factors that are detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms 10-K and
10-Q, or in information disclosed in public conference calls, the date
and time of which are released beforehand. We do not intend to update
any forward-looking statements after the date of this release.
About Genomics England
Genomics England is a company owned by the Department of Health and was
set up to deliver the 100,000 Genomes Project. This flagship project
will sequence 100,000 whole genomes from NHS patients and their families.
Genomics England has four main aims:
to bring benefit to patients
to create an ethical and transparent programme based on consent
to enable new scientific discovery and medical insights
to kickstart the development of a UK genomics industry
The project is focusing on patients with rare diseases, and their
families, as well as patients with common cancers. For more information
View source version on businesswire.com: http://www.businesswire.com/news/home/20170626005362/en/
Source: Illumina, Inc.
Rebecca Chambers, 858-255-5243
David Robertson, +44 (0)1223 824909
Europe, Middle East,
Jen Carroll, 858-882-6822
Katrina Nevin-Ridley, 0207 882 6493